NewAmsterdam Pharma Stock Hits Day High with 8.41% Surge

NewAmsterdam Pharma Co. NV has experienced a significant uptick in its stock performance, gaining 8.41% on September 26, 2025. The stock reached an intraday high of USD 28.61, reflecting strong market activity. Over the past week, NewAmsterdam has outperformed the S&P 500, with a 6.78% increase compared to the index's decline of 0.31%.
In the last month, the stock has shown a robust growth of 13.14%, while the S&P 500 managed only a 2.75% gain. Impressively, NewAmsterdam's performance over the past year stands at 80.04%, significantly surpassing the S&P 500's 15.64% return. The company has also demonstrated remarkable growth in net sales, which surged by 740.06% to USD 19.14 million, following two consecutive quarters of negative results.

Despite the positive sales growth, NewAmsterdam faces challenges with a negative EBITDA and a pre-tax profit of USD -19.95 million, although this figure has improved by 58.72%. The company maintains a strong institutional ownership at 100%, indicating confidence from larger investors. Overall, NewAmsterdam Pharma Co. NV continues to show a market-beating performance in both the short and long term within the pharmaceuticals and biotechnology sector.